<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EFLORNITHINE HYDROCHLORIDE</span><br/>(e-flor'ni-theen)<br/><span class="topboxtradename">Vaniqa<br/></span><b>Classifications:</b> <span class="classification">skin and mucous membrane agent</span>; <span class="classification">dermatological agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>13.9% cream</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits enzyme activity in the skin that is required for hair growth.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Results in retarding the rate of hair growth.</p>
<h1><a name="uses">Uses</a></h1>
<p>Reduction of unwanted facial hair in women.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to eflornithine or its components; lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category C).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hair Removal</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply thin layer to affected areas of the face and adjacent involved areas under the chin and rub in thoroughly b.i.d. at
               least 8 h apart<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply thin layer to affected skin areas on face and under chin and rub in thoroughly.</li>
<li>Do not wash treated areas for at least 4 h after application.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Facial edema. <span class="typehead">CNS:</span> Dizziness. <span class="typehead">GI:</span> Dyspepsia, anorexia. <span class="typehead">Skin:</span>
<span class="speceff-common">Acne, pseudofolliculitis barbae,</span> stinging, burning, pruritus, erythema, tingling, irritation, rash, alopecia, folliculitis, ingrown hair. 
      <h1><a name="interactions">Interactions</a></h1>No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Metabolism: Not metabolized. <span class="typehead">Elimination:</span> Excreted primarily in urine. <span class="typehead">Half-Life:</span> 8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report skin irritation.</li>
<li>
            							Note: Drug slows growth of facial hair, but is not a depilatory.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>
            							Note: Effect of drug is usually not apparent for 48 wk.
            						
         </li>
<li>Reduce frequency of drug application to once daily if skin irritation occurs. If irritation continues, contact physician.</li>
<li>Do not breast feed while using this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>